How to access Krazati from Bahrain, the named-patient import pathway, 2026
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-13.
A Bahraini patient with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying a KRAS G12C mutation, after at least one prior systemic therapy, or with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (in combination with cetuximab), may receive a prescription for Krazati (adagrasib) from their treating oncologist. Krazati is FDA-approved in the United States and now manufactured by Bristol Myers Squibb following the BMS acquisition of Mirati Therapeutics. It is a small-molecule KRAS G12C covalent inhibitor administered orally. Local availability of Krazati in the Kingdom of Bahrain can be inconsistent: the drug may not be on every oncology pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through the National Health Regulatory Authority (NHRA) remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.
Ask about Krazati in Bahrain
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Krazati covalently binds the cysteine at position 12 of the mutant KRAS G12C protein, locking it in the inactive GDP-bound state. Standard adult dosing is 600 mg orally twice daily. Confirmation of a KRAS G12C mutation by an FDA-approved companion diagnostic, or an equivalent locally accredited next-generation sequencing test, is required before initiation. Baseline workup per FDA labeling includes complete blood count, hepatic function, renal function, electrolytes (magnesium, potassium), ECG (QTc prolongation is a known signal, especially with concomitant QT-prolonging agents or CYP3A inhibitors), and pregnancy testing where applicable. Important warnings include gastrointestinal adverse reactions, QTc interval prolongation, hepatotoxicity, interstitial lung disease and pneumonitis, and embryo-fetal toxicity. Your oncologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Krazati legally importable into Bahrain?
Yes, through the National Health Regulatory Authority (NHRA) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. The Kingdom has an established pathway for specialty oncology medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.
The NHRA named-patient route allows a Bahrain-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility.
How the pathway works, step by step
- Consultation with your treating oncologist. The prescribing decision is clinical. Your oncologist documents the indication, KRAS G12C mutation status (NGS or companion diagnostic report), prior therapies, and rationale for Krazati.
- Baseline screening. CBC, LFTs, renal function, electrolytes, ECG, and pregnancy testing where applicable are confirmed and documented. Concomitant medication review for CYP3A and QT-prolonging interactions is performed.
- NHRA named-patient application. Your oncologist or the hospital's import pharmacy files the application with clinical rationale, mutation status documentation, patient reference, product strength (200 mg tablets), quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from Bristol Myers Squibb's authorised distribution under DSCSA chain-of-custody.
- Shipment. Krazati is an oral tablet with controlled-room-temperature storage requirements. Shipments include temperature-monitored packaging and tamper-evident seals.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your oncologist initiates therapy with scheduled ECG and lab follow-up.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis, KRAS G12C mutation status (with NGS or companion diagnostic report), prior therapy history, and Krazati as the indicated next step
- Verification of their Bahrain medical licence (SCFHS registration)
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening (CBC, LFTs, renal, electrolytes, ECG) consistent with FDA labeling
- The planned dosing strength and schedule (600 mg twice daily; with cetuximab if colorectal indication)
- A discussion note on the QTc monitoring plan and concomitant medication review
Reserve Meds provides a physician documentation kit that bundles the templates NHRA reviewers expect to see for KRAS G12C targeted therapy.
Typical costs and indicative timing
Reserve Meds gives you a transparent, itemised custom quote at intake. Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, NHRA documentation handling, shipping, and coordination add incremental cost. The delivered quote we issue at intake shows each line separately.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling cadence aligned to your monthly supply.
Where Reserve Meds fits in
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Krazati specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for NHRA review, including QTc and CYP3A interaction monitoring templates.
- Logistics. Temperature-monitored, internationally tracked shipment to your named dispensing facility.
- Dedicated case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating oncologist, and dispensing sits with the licensed Bahrain pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.
Frequently asked
Is this legal in Bahrain? Yes, when executed through the NHRA named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across Bahrain oncology.
How does Krazati compare with Lumakras (sotorasib)? Both are KRAS G12C inhibitors. Krazati has CNS penetration data and a separate FDA-approved indication in colorectal cancer with cetuximab. Lumakras (sotorasib) is the alternative G12C inhibitor with a once-daily schedule. Your oncologist makes that determination based on your tumor type, brain metastasis status, and prior therapy.
What about the QTc warning? Krazati can prolong the QTc interval and interacts with CYP3A and other QT-prolonging drugs. Your oncologist will review concomitant medications and schedule ECG monitoring per labeling. Reserve Meds does not make that clinical judgement, your physician does.
Will my private health insurance cover this? Cash-pay is the default posture. Some Bahrain private insurers and CCHI-aligned plans reimburse named-patient oncology imports on a case-by-case basis when the documentation package is strong. We supply documentation for your submission but do not process insurance claims.
What if my oncologist has not filed a named-patient request before? Named-patient import is an institutional process most major Bahrain cancer centers (King Hamad University Hospital (KHUH), Salmaniya Medical Complex, Bahrain Specialist Hospital, American Mission Hospital Bahrain, and Al Hilal Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what NHRA reviewers commonly ask for.
Next step
For Krazati coordination in the Kingdom of Bahrain, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Frequently asked questions
How can I get Krazati in Bahrain if it is not approved or available there?
Reserve Meds coordinates US-sourced Krazati for patients in Bahrain through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Bahrain and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Krazati in Bahrain through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Krazati. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Bahrain, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Krazati in Bahrain through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Krazati to a patient in Bahrain?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Krazati to your treating physician or hospital pharmacy in Bahrain, with appropriate handling for the product.
How long does it take, and what does Krazati in Bahrain cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Krazati in Bahrain?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.